You are here: Industry Insights > cilta-cel

News List

Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen AmericanPharmaceuticalReview
February 15, 2022
Legend Biotech Corporation has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel)...
Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’ pharmatimes
June 03, 2021
Janssen has reported new data for its B-cell maturation antigen (BCMA) directed CAR T therapy ciltacabtagene autoleucel (cilta-cel) in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients.
J&J, Legend's CAR-T therapy cilta-cel granted priority review by FDA firstwordpharma
May 27, 2021
The FDA has accepted a marketing application for Johnson & Johnson and partner Legend Biotech's BCMA-directed CAR-T therapy ciltacabtagene autoleucel (cilta-cel) for priority review as a potential treatment of adults with relapsed and/or refractory
Janssen seeks EU approval for first CAR-T therapy cilta-cel pharmatimes
May 07, 2021
Johnson & Johnson’s (J&J) pharma division Janssen has filed its first CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) with the European Medicines Agency (EMA), seeking approval for the treatment of patients with relapsed/refractory multiple ...